Akeso, Inc.(9926.HK) and Dawnrays Pharmaceutical entered into the Equity Transfer Agreement, AD Pharmaceuticals became an indirect wholly-owned subsidiary of Akeso.

Phase IIl clinical results of Ebronucimab  in Chinese patients with hypercholesterolemia were published at the 《Pharmacological Research》.

The National Medical Products Administration (NMPA) of China has approved the new drug application (NDA) of 伊喜宁® (PCSK9 Monoclonal antibody，Ebronucimab injection) for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolaemia (HeFH).

Phase IIl clinical results of Ebronucimab were published at the European Atherosclerosis Society (EAS 2023)  .

NMPA accepted Ebronucimab (PCSK9) marketing application in two indications：1) primary hypercholesterolemia and mixed hyperlipidemia； 2) heterozygous familial hypercholesterolemia (HeFH).

Phase II clinical results of Ebronucimab in the treatment of Hyperlipidemia were published in a poster session at AHA Scientific Sessions 2022.

The rigistry Phase III clinical trial of Ebronucimab in the treatment of primary hypercholesterolemia patients reached its primary endpoint.

Patient enrollment was completed in the registered clinical study of Ebronucimab in the treatment of heterozygous familial hypercholesterolemia.

AD Pharmaceuticals Puts China-Singapore Guangzhou Knowledge City Base into Operation.

The first-in-human, Phase I clinical study of Pulocimab in the treatment of patients with advanced or metastatic solid tumors was presented at the 2022 American Society of Clinical Oncology (ASCO) annual meeting in a poster session.

Enrollment was completed ahead of schedule for a pivotal Phase III clinical trial for registration purposes of Ebronucimab in the treatment of primary hypercholesterolemia and mixed hyperlipidemia.

A phase II clinical study of Ebronucimab in the treatment of hypercholesterolemia patients at extremely high risk or high risk for cardiovascular disease reached its primary endpoint.

A phase Ib/II clinical study of Pulocimab combined with Cadonilimab (PD-1/CTLA-4 bispecific antibody, AK104) in the treatment of advanced solid tumors was approved in China.

A phase Ib/II clinical study of Pulocimab combined with Cadonilimab (PD-1/CTLA-4 bispecific antibody, AK104) for the treatment of advanced gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction was approved in China.

Enrollment was completed ahead of schedule for a Phase IIb clinical trial of Ebronucimab in the treatment of high-risk/extremely high-risk hypercholesterolemia.

Enrollment was completed for a Phase I clinical trial of Pulocimab in the treatment of advanced solid tumors.

 

The first patient was enrolled in a Phase II clinical trial of Ebronucimab in the treatment of heterozygous familial hypercholesterolemia.

Pulocimab was first approved for clinical trials in China for the treatment of solid tumors.

Ebronucimab was first approved for clinical trials in China for the treatment of hyperlipidemia.

 

AD Pharmaceuticals was established as a joint venture between Akeso, Inc. (9926.HK) and Dawnrays Pharmaceutical (2348.HK), initialized by Dr. Michelle Xia and Dr. Kehan Xu.